Search
Memorial Sloan Kettering experts are available to comment on new research presented at the American Association for Cancer Research 2016 Annual Meeting including immunotherapy and CAR T cells, exercise oncology, precision medicine and more. For more information and to set up interviews or access photos, email Nicole H. McNamara at [email protected].
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.
Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.
At Memorial Sloan Kettering Cancer Center’s 46th annual ceremony, graduating master's and PhD students were honored and award winners were recognized.
Learn how MSK is helping a young mother cope with rectal cancer through the Center for Young Onset Colorectal Cancer, the first program in the country devoted to younger adults with this disease.
The genome-editing technique uncovered several genes previously not known to influence embryonic development.
Meet the students who were awarded fellowships based on academic excellence for the 2020–2021 academic year.
The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.
La terapia dirigida adagrasib recibió una aprobación acelerada para el cáncer colorrectal causado por una mutación llamada KRAS-G12C, cuando se usa en combinación con el fármaco cetuximab. Los investigadores de MSK han liderado gran parte de la investigación que llevó a la aprobación de esta combinación de fármacos.
Open to patients in January 2020, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center provides nearly every aspect of cancer care under one roof.